Prevalence of EGFR Mutations in Vietnamese Patients with Resected Early Stage Non-Small Cell Lung Cancer: EARLY-EGFR Study.

IF 5.1 Q1 ONCOLOGY
Lung Cancer: Targets and Therapy Pub Date : 2025-04-21 eCollection Date: 2025-01-01 DOI:10.2147/LCTT.S494554
Tu Van Dao, Van Luong Dinh, Thanh Vinh Doan, Tri Le Phuong
{"title":"Prevalence of <i>EGFR</i> Mutations in Vietnamese Patients with Resected Early Stage Non-Small Cell Lung Cancer: EARLY-EGFR Study.","authors":"Tu Van Dao, Van Luong Dinh, Thanh Vinh Doan, Tri Le Phuong","doi":"10.2147/LCTT.S494554","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Comprehensive profiling of mutations in the <i>EGFR</i> gene is vital for selecting patients eligible for <i>EGFR</i> targeted therapies.</p><p><strong>Methods: </strong>We investigated the prevalence of <i>EGFR</i> mutations and treatment patterns in patients with early stage non-small cell lung cancer (NSCLC) in Vietnam as a part of EARLY-EGFR (Clinical Trial Identifier: NCT04742192), a global, real-world study. Consecutive patients with surgically resected stage IA-IIIB, non-squamous NSCLC were diagnosed from August 2021 to June 2022 and were prospectively enrolled from November 2021 to July 2022.</p><p><strong>Results: </strong>A total 200 patients (age: median [range], 60.0 [30.0-80.0] years) were enrolled from 3 centers; 56.0% were males and 64.0% never smoked. The prevalence of <i>EGFR</i> mutations was 51.0% (102/200) including deletions in <i>exon-19</i> (49.0%) and <i>exon-21 L858R</i> mutations (33.3%). Females (73.9%, 65/88), patients aged ≥60 years (52.5%, 53/101), nonsmokers (61.2%, 63/103) and those with stage I (55.8%, 67/120) had higher prevalence of <i>EGFR</i> mutations. Multivariate analysis (adjusted odds ratio [aOR]) showed <i>EGFR</i> mutations to be significantly associated (p < 0.05) with female gender (aOR = 5.90), age ≥60 years (aOR = 1.05), and stage III disease (vs stage I) (aOR = 0.30).</p><p><strong>Conclusion: </strong>These results underscore the need for <i>EGFR</i> testing early in management algorithm of NSCLC in Vietnam to identify patients eligible for targeted therapy in concordance with international guidelines.</p>","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":"16 ","pages":"39-49"},"PeriodicalIF":5.1000,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12025828/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer: Targets and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/LCTT.S494554","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Comprehensive profiling of mutations in the EGFR gene is vital for selecting patients eligible for EGFR targeted therapies.

Methods: We investigated the prevalence of EGFR mutations and treatment patterns in patients with early stage non-small cell lung cancer (NSCLC) in Vietnam as a part of EARLY-EGFR (Clinical Trial Identifier: NCT04742192), a global, real-world study. Consecutive patients with surgically resected stage IA-IIIB, non-squamous NSCLC were diagnosed from August 2021 to June 2022 and were prospectively enrolled from November 2021 to July 2022.

Results: A total 200 patients (age: median [range], 60.0 [30.0-80.0] years) were enrolled from 3 centers; 56.0% were males and 64.0% never smoked. The prevalence of EGFR mutations was 51.0% (102/200) including deletions in exon-19 (49.0%) and exon-21 L858R mutations (33.3%). Females (73.9%, 65/88), patients aged ≥60 years (52.5%, 53/101), nonsmokers (61.2%, 63/103) and those with stage I (55.8%, 67/120) had higher prevalence of EGFR mutations. Multivariate analysis (adjusted odds ratio [aOR]) showed EGFR mutations to be significantly associated (p < 0.05) with female gender (aOR = 5.90), age ≥60 years (aOR = 1.05), and stage III disease (vs stage I) (aOR = 0.30).

Conclusion: These results underscore the need for EGFR testing early in management algorithm of NSCLC in Vietnam to identify patients eligible for targeted therapy in concordance with international guidelines.

EGFR突变在越南早期非小细胞肺癌切除术患者中的流行:早期EGFR研究
全面分析EGFR基因突变对于选择适合EGFR靶向治疗的患者至关重要。方法:我们调查了越南早期非小细胞肺癌(NSCLC)患者中EGFR突变的患病率和治疗模式,作为早期EGFR(临床试验标识符:NCT04742192)的一部分,这是一项全球性的真实世界研究。于2021年8月至2022年6月诊断为手术切除的IA-IIIB期非鳞状NSCLC的连续患者,并于2021年11月至2022年7月前瞻性入组。结果:共纳入来自3个中心的200例患者(年龄:中位数[范围],60.0[30.0-80.0]岁);56.0%为男性,64.0%从不吸烟。EGFR突变发生率为51.0%(102/200),其中外显子19缺失(49.0%)和外显子21缺失L858R突变(33.3%)。女性(73.9%,65/88)、年龄≥60岁(52.5%,53/101)、非吸烟者(61.2%,63/103)和I期患者(55.8%,67/120)的EGFR突变发生率较高。多因素分析(校正优势比[aOR])显示,EGFR突变与女性(aOR = 5.90)、年龄≥60岁(aOR = 1.05)、III期疾病(aOR = 0.30)显著相关(p < 0.05)。结论:这些结果强调了在越南NSCLC的早期管理算法中进行EGFR检测的必要性,以确定符合国际指南的靶向治疗的患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
8.10
自引率
0.00%
发文量
10
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信